

Travel Fund for GBM Clinical Trial Patients



Immunomic Therapeutics, Inc. is sponsoring a travel fund for patients enrolled in the ATTAC-II trial (NCT02465268)

Trial Overview

A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma

Study Chair

Duane Mitchell, MD, PhD, University of Florida

Locations

- UF Health, Gainesville, FL
- Orlando Health | UF Health, Orlando, FL
- Duke University Medical Center, Durham, North Carolina

Sponsors and Collaborators

- University of Florida
- National Cancer Institute (NCI)

Travel Fund Details

Travel for enrolled patients living more than 100 miles away from the trial sites will be sponsored for the duration of treatment

Travel Arrangements Will Include

- Roundtrip coach flights for the patient and up to 1 caregiver
- Hotel accommodations for each visit (1-2 nights, depending on treatment)
- Car rental for each visit

Contact

Phuong Deleyrolle, RN

Telephone. (352) 273-5529

Email. pdeleyrolle@ufl.edu

For more information about the trial and the travel fund visit:

<https://www.immunomix.com/gbm-travel-fund/>